Mode
Text Size
Log in / Sign up
N/A N=23 Other

Pre-Study of Wild Type Enterotoxigenic E. Coli (ETEC) Strain for Verification of a Planned Challenge Dose

ETEC Diarrhea

Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Number of Participants With Moderate and Severe Diarrhea — 17 participants moderate or severe diarrea

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Enterotoxigenic E. coli (ETEC) strain (Other)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Scandinavian Biopharma AB
Primary completion
Feb 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Moderate and Severe Diarrhea
17
PRIMARY
Subjects Developing Moderate-to-Severe Diarrhea Following Oral Challenge
74

Summary

This was an open-label, single-site pre-study designed to evaluate the safety, tolerability, and infectivity of wild-type Enterotoxigenic Escherichia coli (ETEC) strain E24377A in healthy adults. The aim was to estimate the incidence of moderate and severe diarrhea following oral challenge with approximately 4 × 10⁹ colony forming units (cfu) of the strain. A total of 23 participants were enrolled and monitored in an inpatient setting after receiving a single challenge dose. Clinical signs, symptoms, and stool output were assessed over 120 hours. This challenge model was developed to support a future controlled human infection study (CHIM) evaluating an oral inactivated ETEC vaccine.

Eligibility Criteria

Inclusion Criteria

  • Healthy adults between 18 and 50 years of age, inclusive, at the time of signing the informed consent.
  • General good health, without clinically significant medical history, physical examination findings or clinical laboratory abnormalities per clinical judgment of PI.
  • Negative pregnancy test at screening and prior to challenge for people of childbearing potential. People of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence is acceptable. People of childbearing potential unable to bear children must have this documented (e.g. tubal ligation or hysterectomy) or must have negative pregnancy tests at screening and prior to challenge.
  • Willingness to participate in the study after all aspects of the protocol have been explained and written informed consent obtained.
  • Completion of a training session and demonstrated comprehension of the protocol procedures and knowledge of ETEC associated illness by passing a written examination (70% pass score).
  • Availability for the study duration, including planned follow-up visit/contact.

Exclusion Criteria

  • Presence of a significant medical or psychiatric condition which in the opinion of the investigator precludes participation in the study, including gastrointestinal disease (gastritis, irritable bowel disease as suggested by Rome III criteria or medical diagnosis, inflammatory bowel disease). Some medical conditions which are adequately treated and stable would not preclude entry into the study. These conditions might include stable asthma controlled with inhalers or mild hypertension stably controlled.
  • Significant abnormalities in screening haematology, or serum chemistry as determined by PI.
  • Presence in the serum of HIV antibody, HBsAg, or HCV antibody with confirmation of infection (e.g. by HCV PCR).
  • Evidence of IgA deficiency (serum IgA two months in ETEC endemic countries during the last 10 years, OR planned travel to endemic countries prior to study day 180.
  • Vaccination for or ingestion of ETEC, cholera, or LT toxin within 5 years prior to dosing.
  • Use of antibiotics during the 14 days before challenge dosing or proton pump inhibitors, H2 blockers or antacids within 48 hours prior to challenge dosing.
  • History of diarrhea in the 7 days prior to challenge (outpatient diarrhea is defined as ≥ 3 unformed (grade 3 or greater) loose stools in 24 hours).
  • Known allergy to two of the three following antibiotics: ciprofloxacin, amoxicillin, and/or azithromycin.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06290089). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search